Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · May 19, 2024

Prognostic Value of EndoPredict in Patients With HR+/HER2− Primary Breast Cancer



Additional Info

Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trial
ESMO Open 2024 Apr 30;9(5)103443, F Penault-Llorca, F Dalenc, S Chabaud, P Cottu, D Allouache, D Cameron, J Grenier, L Venat Bouvet, A Jegannathen, M Campone, M Debled, AC Hardy-Bessard, S Giacchetti, P Barthelemy, L Kaluzinski, A Mailliez, MA Mouret-Reynier, E Legouffe, A Cayre, M Martinez, C Delbaldo, D Mollon-Grange, EJ Macaskill, M Sephton, L Stefani, B Belgadi, M Winter, H Orfeuvre, M Lacroix-Triki, H Bonnefoi, J Bliss, JL Canon, J Lemonnier, F Andre, T Bachelot

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading